Cited by 163Attention Deficit Hyperactivity DisorderSchizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial

Open access
KOOIJ, J. J. S., BURGER, H., BOONSTRA, A. M., VAN DER LINDEN, P. D., KALMA, L. E., BUITELAAR, J. K.·2004·Psychological Medicine

Abstract

Background. Data on the efficacy and safety of methylphenidate in adults with attention deficit/hyperactivity disorder (ADHD) are lacking in Europe. This study was undertaken to report on the efficacy and safety of methylphenidate in an adult out-patient population with ADHD, and to compare results with US data. Method. A double-blind randomized cross-over trial comparing methylphenidate and placebo in 45 adults with ADHD with childhood onset was performed in a dose–titration design. Methylphenidate was titrated from 0·5 mg/kg per day in week 1 up to 1·0 mg/kg per day in week 3. Results. Response rates using methylphenidate varied between 38 and 51%, and using placebo between 7 and 18% ( p <0·05), depending on outcome measure used. Although the overall percentage of subjects having any side effect on both methylphenidate and placebo was rather high, side effects on methylphenidate over and above those on placebo were few and mild. Conclusions. Methylphenidate proves to be an effective and well tolerated treatment for symptoms of ADHD in adults in the short term. Future research should study the long-term response and clarify the impact of gender, co-morbidity, socio-economic status and IQ on response rates in adults with ADHD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0033291703001776

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In adults, comorbidity is the rule, with 75% of clinical patients having at least one other disorder, and mean number of psychiatric comorbidities being three.

    “Similarly in adults, co-morbidity is the rule, with 75% of clinical patients having at least one other disorder, and the mean number of psychiatric comorbidities being three [41,148].”
  • Comorbidity is the rule rather than the exception in adult ADHD.

    “Comorbidity being the rule rather than the exception, the evaluation of co-occurring symptoms, syndromes and disorders must always be part of the clinical assessment of adult ADHD [148,150].”
  • Side-effects of stimulants are usually mild and transitory, mainly consisting of headache, reduced appetite, palpitations, nervousness, difficulty falling asleep, and dry mouth.

    “Side-effects are usually mild and transitory, mainly consisting of headache, reduced appetite, palpitations, nervousness, difficulty falling asleep, and dry mouth [148,269,270].”
  • Compliance to frequent dosing regimens is poor in ADHD patients due to forgetfulness, inattentiveness and self-organisation problems, leading to daily instability by frequent rebound symptoms and ineffective treatment.

    “Compliance to such frequent dosing regimens is however poor in ADHD patients due to forgetfulness, inattentiveness and self-organisation problems, leading to daily instability by frequent rebound symptoms and ineffective treatment [148,289-291].”
  • Adults require repetitive dosing with immediate release stimulants, of between three to four doses in most cases, and more often in others, to avoid rebound symptoms and for adequate control of ADHD symptoms during the day and evening.

    “The requirement for a longer duration of activity in adults, requires repetitive dosing with immediate release stimulants, of between three to four doses in most cases, and more often in others, to avoid rebound symptoms and for adequate control of ADHD symptoms during the day and evening [148,270].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 29 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Barkley, R. A. (1990). Attention-Deficit Hyperacitivity Disorder. A Handbook for Diagnosis and Treatment. The Guilford Press : New York.
  2. NIMH (1985). CGI (Clinical Global Impression) Scale. Psycho- pharmacology Bulletin 21, 839-844.
  3. Prince, J. & Wilens, T. (2002). Medications used in the treatment of AD/HD in women. In Gender Issues and AD/HD (ed. P. Quinn and K. Nadeau), pp. 144-182. Advantage Books : Silver Spring.

Cited by

Sorted by citations

Authors
KOOIJ, J. J. S., BURGER, H., BOONSTRA, A. M., VAN DER LINDEN, P. D., KALMA, L. E., & BUITELAAR, J. K.
Affiliations
Radboud University Medical Center (NL)
Venue
Psychological Medicine
Published
2004-08
Volume
34
Issue
6
Pages
973-982
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W2093719531
Cited by
163
References
29
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2022: 1 · 2021: 7 · 2020: 5 · 2019: 5 · 2018: 1 · 2017: 1 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 12 · 2012: 13
FWCI
7.67
Type
journal article
Language
en
Open access
Locations
  • Psychological Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
  • VU Research Portal (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Hersenstichting
  • Nationaal Fonds Geestelijke Volksgezondheid
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
methylphenidate, adult ADHD, ADHD medication, dose titration, treatment efficacy, drug safety, adverse effects, childhood-onset ADHD, outpatients
MeSH terms
Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Double-Blind Method, Female, Humans, Male, Methylphenidate, Middle Aged, Placebos, Treatment Outcome, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review